Optimization Compounds Sample Clauses

The 'Optimization Compounds' clause defines which chemical compounds are considered as part of the optimization process within a research or development agreement. Typically, this clause specifies the criteria or characteristics that a compound must meet to be classified as an optimization compound, such as being derived from initial lead compounds or meeting certain activity thresholds. By clearly delineating which compounds fall under this category, the clause helps allocate rights, responsibilities, and potential benefits related to further development, ensuring clarity and preventing disputes over compound ownership or usage.
Optimization Compounds. Optimization Compounds, their structures and best methods of synthesis and manufacture developed during the Optimization Program shall be made available only to ICOS for research or application to any Optimization Target, within or outside the Collaboration, during the Optimization Period, and Array shall not work on or provide information regarding such Optimization Compound to any Third Party, except to take any steps necessary to protect ICOS's exclusivity hereunder.
View SourceView Similar (3)

Related to Optimization Compounds

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Manufacturing (a) The Supplier shall without limitation be responsible, at no additional cost to the Purchaser, for: sourcing and procuring all raw materials for the Products; obtaining all necessary approvals, permits and licenses for the manufacturing of the Products; providing sufficient qualified staff and workers to perform the obligations under this Purchase Agreement; implementing and maintaining effective inventory and production control procedures with respect to the Products; and handling other matters as reasonably requested by the Purchaser from time to time. (b) The Supplier shall not change any process, material, component, packaging or manufacturing location without the Purchaser’s express prior written approval.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.